Mutations in exon 19 and 21 are responsible for 90% EGFR mutations in lung adenocarcinoma and sensitive to the targeted drugs.[25] Recently, some studies found that there was little difference in the treatment and prognosis between exon 19 deletion and exon 21 mutation. This evidence concerns the gene EGFR and lung adenocarcinoma.